Compare DexCom, Inc. (DXCM) vs Centrus Energy Corp (LEU) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

Centrus Energy (LEU) trades at $147.83, down 7.25% today, with a bearish technical signal from moving averages. The stock shows mixed fundamentals with a high P/E of 56.92 but strong recent contract wins, including a $1 billion DOE award for nuclear fuel production. Recent earnings beat expectations in Q1 2026 but missed in prior quarters. Positive news includes inclusion in the S&P SmallCap 600 and a letter of intent with Oklo for HALEU supply.

Outlook is cautiously optimistic due to strategic government contracts and nuclear industry tailwinds, but high valuation and recent earnings misses pose risks. Analyst consensus is a Buy with a $223.14 price target, implying significant upside. Key risks include execution on new contracts and volatility in uranium markets.